The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Increase In Market Value Is Predicted For The Biomarker Clinical Phase Outsourcing Services Market During The 2026–2030 Period?
The biomarker clinical phase outsourcing services market has undergone substantial expansion in recent years. Its value is anticipated to rise from $11.91 billion in 2025 to $14.62 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.7%. This past growth can be attributed to several factors, including the increasing complexity of clinical trial designs, a surge in oncology clinical research activity, the progression of biomarker-driven drug development, the broadening of translational research programs, and enhanced collaboration with specialized service providers.
The biomarker clinical phase outsourcing services market size is projected to experience substantial expansion over the coming years. This market is anticipated to reach $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. Factors driving this growth during the forecast period include the escalating demand for personalized medicine trials, the increasing integration of AI-driven biomarker analytics, the broadened scope of multi-biomarker clinical studies, rising investments in precision oncology, and heightened regulatory focus on biomarker validation. Key trends anticipated within the forecast period encompass a surge in the outsourcing of biomarker clinical trial activities, the expanding application of predictive and prognostic biomarkers, the increasing incorporation of omics-based biomarker analysis, the progression of companion diagnostics development, and a sharpened emphasis on precision medicine trials.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp
Which Core Factors Are Supporting The Expansion Of The Biomarker Clinical Phase Outsourcing Services Market?
The expansion of clinical trials is projected to fuel the advancement of the biomarker clinical phase outsourcing services market in the future. Clinical trials are investigative studies performed with human subjects to assess the safety and efficacy of new medical treatments, interventions, or diagnostic methodologies. This increase in clinical trials is supported by progress in medical research, a higher occurrence of chronic illnesses, greater financial backing from both public and private sources, and a growing need for innovative treatments and therapies. Outsourcing providers frequently possess specialized expertise and experience in biomarker identification, validation, and analysis. This expertise can enhance the quality and reliability of the biomarker data gathered throughout a trial. For example, in November 2025, the National Library of Medicine, a US-based biomedical library, reported that ClinicalTrials.gov currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Consequently, the rise in clinical trials will propel the growth in the biomarker clinical phase outsourcing services market.
How Is The Biomarker Clinical Phase Outsourcing Services Market Examined Through Segment Analysis?
The biomarker clinical phase outsourcing services market covered in this report is segmented –
1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types
2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis
3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies, Biotechnology Companies
Subsegments:
1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers
2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers
3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers
4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers
5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers
Which Trends Are Supporting The Evolution Of The Biomarker Clinical Phase Outsourcing Services Market?
Leading companies in biomarker clinical phase outsourcing services are concentrating on improvements involving high-throughput flow cytometry and ELISpot testing to achieve a competitive advantage in the market. These advanced testing methods are employed for biomarker analysis, delivering swift and accurate evaluations of immune responses and cellular markers. For example, in May 2024, KCAS Bio, a U.S.-based bioanalytical Contract Research Organization providing GLP/GCP-compliant biomarker and immune-monitoring services, formed a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO specializing in ELISpot and flow cytometry assays. Through this partnership, KCAS Bio installed harmonized spectral cytometers at Crux Biolabs’ facilities, granting clients access to high-throughput, multiparametric flow cytometry across the U.S., Europe, and Australia. This collaboration reinforces KCAS’s biomarker development and immune-monitoring capabilities by enabling quick and precise assessment of cellular biomarkers in clinical trials, empowering clients to generate high-quality data that supports regulatory submissions and expedites drug development.
Who Are The Companies Shaping The Biomarker Clinical Phase Outsourcing Services Market Landscape?
Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.
Access The Complete Biomarker Clinical Phase Outsourcing Services Market Report:
Which Region Accounts For The Highest Share Of The Biomarker Clinical Phase Outsourcing Services Market?
North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Biomarker Clinical Phase Outsourcing Services Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp
Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company
Biomarker Discovery Outsourcing Services Global Market Report 2026
Clinical Biomarkers Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Biologics Outsourcing Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model